Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEM NASDAQ:FHTX NASDAQ:PHAR NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$16.44+7.0%$14.29$5.68▼$16.74$1.01B-0.09830,944 shs1.88 million shsFHTXFoghorn Therapeutics$4.28+0.2%$4.67$3.27▼$6.95$251.28M2.97162,645 shs104,652 shsPHARPharming Group$12.99-4.9%$15.42$9.54▼$21.34$917.35M0.0422,958 shs21,756 shsSDGRSchrodinger$15.20+7.3%$12.18$10.94▼$27.63$1.12B1.571.39 million shs2.34 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics-1.03%+9.87%+19.91%-0.90%+95.92%FHTXFoghorn Therapeutics0.00%+2.64%-17.41%-24.82%-0.70%PHARPharming Group+0.74%+6.64%-16.81%-16.20%+32.88%SDGRSchrodinger+6.95%+7.03%+15.69%+17.41%-34.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$16.44+7.0%$14.29$5.68▼$16.74$1.01B-0.09830,944 shs1.88 million shsFHTXFoghorn Therapeutics$4.28+0.2%$4.67$3.27▼$6.95$251.28M2.97162,645 shs104,652 shsPHARPharming Group$12.99-4.9%$15.42$9.54▼$21.34$917.35M0.0422,958 shs21,756 shsSDGRSchrodinger$15.20+7.3%$12.18$10.94▼$27.63$1.12B1.571.39 million shs2.34 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics-1.03%+9.87%+19.91%-0.90%+95.92%FHTXFoghorn Therapeutics0.00%+2.64%-17.41%-24.82%-0.70%PHARPharming Group+0.74%+6.64%-16.81%-16.20%+32.88%SDGRSchrodinger+6.95%+7.03%+15.69%+17.41%-34.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 2.67Moderate Buy$30.7587.04% UpsideFHTXFoghorn Therapeutics 2.88Moderate Buy$11.43167.02% UpsidePHARPharming Group 2.40Hold$38.33195.10% UpsideSDGRSchrodinger 2.33Hold$20.2533.22% UpsideCurrent Analyst Ratings BreakdownLatest FHTX, SDGR, PHAR, and CGEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/14/2026SDGRSchrodinger Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $17.005/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/8/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $37.005/4/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/28/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/28/2026CGEMCullinan Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $30.004/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/21/2026FHTXFoghorn Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026CGEMCullinan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$5.96 per shareN/AFHTXFoghorn Therapeutics$30.91M8.13N/AN/A($1.30) per share-3.29PHARPharming Group$376.13M2.44$0.19 per share66.86$3.81 per share3.41SDGRSchrodinger$255.87M4.39N/AN/A$4.25 per share3.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%8/6/2026 (Estimated)FHTXFoghorn Therapeutics-$74.28M-$1.16N/AN/AN/A-266.88%N/A-35.38%8/4/2026 (Estimated)PHARPharming Group$2.85M$0.1681.1919.98N/A3.30%4.64%2.55%7/30/2026 (Estimated)SDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)Latest FHTX, SDGR, PHAR, and CGEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A5/7/2026Q1 2026FHTXFoghorn Therapeutics-$0.28-$0.29-$0.01-$0.29$7.94 million$3.27 million5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 million3/11/2026Q4 2025FHTXFoghorn Therapeutics-$0.30-$0.34-$0.04-$0.34$9.50 million$9.25 million3/10/2026Q4 2025CGEMCullinan Therapeutics-$0.80-$0.77+$0.03-$0.77$5.56 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A10.2810.28FHTXFoghorn TherapeuticsN/A2.922.92PHARPharming Group0.352.632.06SDGRSchrodingerN/A2.742.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%FHTXFoghorn Therapeutics61.55%PHARPharming Group0.03%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics8.60%FHTXFoghorn Therapeutics7.58%PHARPharming Group2.07%SDGRSchrodinger10.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableFHTXFoghorn Therapeutics12058.71 million54.26 millionOptionablePHARPharming Group28070.62 million69.16 millionNot OptionableSDGRSchrodinger79073.82 million66.37 millionOptionableFHTX, SDGR, PHAR, and CGEM HeadlinesRecent News About These CompaniesSchrodinger (NASDAQ:SDGR) and Hinge Health (NYSE:HNGE) Head-To-Head SurveyMay 29 at 4:47 AM | americanbankingnews.comA Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26.55 vs Price $14.15May 28 at 11:01 PM | gurufocus.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 22, 2026 | businesswire.comMovano (NASDAQ:MOVE) vs. Schrodinger (NASDAQ:SDGR) Head to Head AnalysisMay 20, 2026 | americanbankingnews.comSchrödinger Balances Growth and Losses in Earnings CallMay 20, 2026 | tipranks.com7 Healthcare AI Stocks Under $50 With Huge Upside PotentialMay 18, 2026 | 247wallst.comSchrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comUBS Group AG Buys 489,059 Shares of Schrodinger, Inc. $SDGRMay 11, 2026 | marketbeat.comSchrodinger (NASDAQ:SDGR) Downgraded to Strong Sell Rating by Wall Street ZenMay 9, 2026 | marketbeat.comEarnings Update: Schrödinger, Inc. (NASDAQ:SDGR) Just Reported And Analysts Are Trimming Their ForecastsMay 8, 2026 | finance.yahoo.comSchrödinger (SDGR) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comA Look At Schrödinger (NasdaqGS:SDGR) Valuation After Q1 Earnings And Hosted AI Software PushMay 6, 2026 | finance.yahoo.comSchrödinger, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6, 2026 | seekingalpha.comSchrodinger Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comSchrödinger, Inc. (SDGR) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSchrödinger Earnings Call: Growth Now, Profits LaterMay 5, 2026 | tipranks.comSchrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2026 | zacks.comSchrodinger (NASDAQ:SDGR) Issues Earnings ResultsMay 5, 2026 | marketbeat.comSchrödinger Reports First Quarter 2026 Financial ResultsMay 5, 2026 | businesswire.comHere’s What the Street Thinks About Schrödinger (SDGR)May 5, 2026 | insidermonkey.comSchrodinger: AI Threat Is Looming Large (Rating Downgrade)April 22, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026Amylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026FHTX, SDGR, PHAR, and CGEM Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$16.44 +1.08 (+7.03%) Closing price 04:00 PM EasternExtended Trading$16.31 -0.13 (-0.80%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Foghorn Therapeutics NASDAQ:FHTX$4.28 +0.01 (+0.23%) Closing price 04:00 PM EasternExtended Trading$4.28 0.00 (0.00%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Pharming Group NASDAQ:PHAR$12.99 -0.67 (-4.90%) Closing price 04:00 PM EasternExtended Trading$13.04 +0.05 (+0.38%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Schrodinger NASDAQ:SDGR$15.20 +1.04 (+7.34%) Closing price 04:00 PM EasternExtended Trading$15.34 +0.14 (+0.89%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
